THE
INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE
COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE
MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK
DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018,
AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS
CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN
PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL
THEREFORE CEASE TO BE IN POSSESSION OF INSIDE
INFORMATION.
4 April 2024
Genflow
Biosciences Plc
Successful Placing and
Subscription To Raise £715,000, Grant of Warrants and PDMR
Notifications
Genflow Biosciences Plc (LSE:GENF)
(OTCQB:GENFF) ("Genflow" or "the Company") which is rapidly becoming the major European exponent in the
successful development of therapeutic longevity solutions
for the
prevention of age-related diseases, is pleased to announce it has
raised, through its broker Capital Plus Partners, £715,000
(before expenses) by way of a placing and subscription of
57,200,000 new Ordinary Shares of 1.25 pence each (the "Placing")
(the "Placing Shares").
Further, each two Placing Shares
will have one warrant attached, exercisable at 2 pence per
share for three years from the date of issue. Holders of these
warrants will not, however, be able to exercise the same for a
period of one year from the date of grant.
Director Participation
All Directors participated in the
Placing with the CEO Dr Eric Leire investing £50,000 personally,
the details of such participation are set out below. No
Warrants are being issued to Directors.
Use
of Proceeds
The net proceeds from the Placing
will be used to continue development and associated clinical
trials. The near-term clinical trials are aimed at a potential cure
of the liver disease NASH which currently effects over 40 million
people worldwide: in addition to conference participation and an
enhanced investor relations program.
Dr. Eric Leire, CEO of Genflow,
commented: "We are delighted to have raised this additional
funding, noting the participation of Premier Miton, a well-known UK
institution. The success of this capital raise clearly reflects the
growing interest among UK institutional investors in the field of
longevity research. Interest amongst US institutional investors in
the Longevity sector is already well ahead of Europe, but we
believe we have a unique approach to address the growing issues of
age-related diseases.
Broker Warrants
2,860,000 warrants were issued to
Capital Plus Partners Ltd as part of its broker fee, on the same
terms set out above.
Application for Admission
The new ordinary shares to be issued
pursuant to the Placing will represent 19.56 per cent of
the issued ordinary share capital of the Company prior to the
Placing. The Company will apply for admission of the Placing Shares
to listing on the standard listing segment of the Official List of
the FCA and to trading on the main market for listed
securities of the London Stock Exchange .The Placing
Shares will rank pari
passu in all respects with the existing ordinary shares
of £0.0003 in the capital of the Company. The
Placing Shares are expected to be admitted for trading on or
around 9 April 2024.
Total Voting Rights
In accordance with the provision of
the Disclosure Guidance and Transparency Rules of
the FCA ("DTRs"), the Company confirms that, following
admission, its issued share capital will
comprise 349,706,618 Ordinary Shares, each of which
carries the right to vote, with no Ordinary Shares held in
treasury. This figure may be used by Shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the DTRs
The Directors of the Company accept
responsibility for the contents of this announcement.
Contacts
|
Joint Corporate Brokers
|
|
|
Clear Capital Markets
|
Capital Plus Partners Ltd
|
|
Bob Roberts, +44 203 869
6080
|
Dominic Berger, +44 203 821
6167
|
|
|
Keith Swann, +44 203 821
6169
|
|
|
Jon Critchley, +44 203 821
6168
|
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences
Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company
headquartered in the UK with R&D facilities in Belgium, is
pioneering gene therapies to decelerate the aging process, with the
goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging
global population. Genflow's lead compound, GF-1002, works through
the delivery of a centenarian variant of the SIRT6 gene which has
yielded promising preclinical results. Scheduled to begin in 2025,
Genflow's clinical trial aims to explore the potential benefits of
GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most
prevalent chronic liver disease for which there are no effective
treatments. Please visit www.genflowbio.com
and follow the Company on LinkedIn and
Twitter/X.
PDMR Notifications
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Eric Leire
|
|
2.
|
Reason for notification
|
|
|
a)
|
Position/Status
|
Chief Executive Officer
|
|
b)
|
Initial notification/
Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Genflow Biosciences Plc
|
|
b)
|
LEI
|
213800HVOFXRXVEGDN62
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification Code
|
Ordinary Shares of
£0.0003 per share par
value
ISIN: GB00BP2C3V08
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.25p
|
4,000,000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
-
Aggregated Volume
-
Price
|
Single transaction as in 4 c)
above
|
Price(s)
|
Volume(s)
|
|
1.25p
|
4,000,000
|
|
|
e)
|
Date
of the transaction
|
3
April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Tamara Joseph
|
|
2.
|
Reason for notification
|
|
|
a)
|
Position/Status
|
Non Executive Director
|
|
b)
|
Initial notification/
Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Genflow Biosciences Plc
|
|
b)
|
LEI
|
213800HVOFXRXVEGDN62
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification Code
|
Ordinary Shares of
£0.0003 per share par
value
ISIN: GB00BP2C3V08
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
-
Aggregated Volume
-
Price
|
Single transaction as in 4 c)
above
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
e)
|
Date
of the transaction
|
3
April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Yassine Bendiabdallah
|
|
2.
|
Reason for notification
|
|
|
a)
|
Position/Status
|
Non Executive Director
|
|
b)
|
Initial notification/
Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Genflow Biosciences Plc
|
|
b)
|
LEI
|
213800HVOFXRXVEGDN62
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification Code
|
Ordinary Shares of
£0.0003 per share par
value
ISIN: GB00BP2C3V08
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
-
Aggregated Volume
-
Price
|
Single transaction as in 4 c)
above
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
e)
|
Date
of the transaction
|
3
April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Peter King-Lewis
|
|
2.
|
Reason for notification
|
|
|
a)
|
Position/Status
|
Non Executive Director
|
|
b)
|
Initial notification/
Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Genflow Biosciences Plc
|
|
b)
|
LEI
|
213800HVOFXRXVEGDN62
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification Code
|
Ordinary Shares of
£0.0003 per share par
value
ISIN: GB00BP2C3V08
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
-
Aggregated Volume
-
Price
|
Single transaction as in 4 c)
above
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
e)
|
Date
of the transaction
|
3
April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1.
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Guy Charles Fanneau de la
Horie
|
|
2.
|
Reason for notification
|
|
|
a)
|
Position/Status
|
Non Executive Director
|
|
b)
|
Initial notification/
Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Genflow Biosciences Plc
|
|
b)
|
LEI
|
213800HVOFXRXVEGDN62
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification Code
|
Ordinary Shares of
£0.0003 per share par
value
ISIN: GB00BP2C3V08
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
|
|
|
|
|
d)
|
Aggregated information
-
Aggregated Volume
-
Price
|
Single transaction as in 4 c)
above
|
Price(s)
|
Volume(s)
|
|
1.25p
|
800,000
|
|
|
e)
|
Date
of the transaction
|
3
April 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|